Biotechnology

Aspira Women's Health Inc. Announces Receipt of Delisting Notification from Nasdaq

April 16, 2025 4:00 PM

Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that on April 15, 2025, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's shares from Nasdaq...

Read more

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

April 16, 2025 8:30 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in the Virtual Investor Closing Bell Series on Tuesday, April 22, 2025 at 4:00 PM ET. As part of the event, Mr. Berman will provide a corporate overview and discuss the Company's portfolio of novel...

Read more

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

April 15, 2025 9:00 AM

Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the appointment of Vincent LoPriore, Founder of Gravitas Capital and Co-Founder of President Street Global, to its Board of Directors, increasing the size of the Board to seven Directors. This appointment strengthens Tharimmune's strategic leadership and will support the company's next phase of growth and...

Read more

Baylink Biosciences To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting

April 15, 2025 7:00 AM

Baylink Biosciences today announced that new preclinical data from its portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025, in Chicago, IL. These data provide insights into the potential of Baylink's innovative Antibody Drug Conjugate platform in treatment of cancers with high unmet medical need. Scientists at Baylink have invented a platform technology that enables the...

Read more

Inside Information: Faron Announces Positive Phase II Results in Higher-risk Myelodysplastic Syndrome

April 15, 2025 2:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/r HR MDS) Key Highlights Topline read-out from the Phase II BEXMAB trial confirms earlier positive findings in both frontline and relapsed/refractory higher-risk myelodysplastic syndrome (HR MDS) patients The combination of bexmarilimab and azacitidine remains very well tolerated Full data has...

Read more

PulpFixin Announces Strategic Distribution Partnership with Wildcat Laboratory Solutions to Expand Sustainable Lab Products Across the UK And EU

April 14, 2025 12:00 PM

PulpFixin, an innovator of sustainable laboratory products, announced today a new distribution partnership with Wildcat Laboratory Solutions (www.wildcatls.com), a leading provider of lab equipment and solutions across the United Kingdom and European Union. This strategic collaboration marks a significant step forward in delivering eco-conscious, high-performance alternatives to single-use plastic products in biotech and pharmaceutical labs...

Read more

Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)

April 14, 2025 7:00 AM

Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a commercial stage biopharmaceutical company focused on using lipid technology to develop products to treat diseases with significant unmet medical needs, announced today a non-brokered private placement of preferred shares in the capital of Lobe Sciences' newly created subsidiary Cynaptec Pharmaceuticals, Inc. ("Cynaptec") for an initial gross proceeds of...

Read more

Bionoid Pharma Inc. Announces Completion of 2024 Financial Audit

April 11, 2025 7:30 AM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the successful completion of its audited financial statements for the fiscal year ended December 31, 2024. The audit was conducted by Aloba Awomolo & Partners LLP, Chartered Professional Accountants, who were engaged earlier this year as Bionoid's external auditor. "This marks an important milestone for Bionoid," said Wayne Cockburn, CEO of Bionoid Pharma. "Completing our...

Read more

Elizabeth Fraley, CEO of Kinder Ready, Launches a Summer Learning Initiative with Proven Strategies to Boost Early Mathematics for Young Learners

April 11, 2025 7:25 AM

Elizabeth Fraley Kinder Ready, is excited to announce a new Summer Learning Initiative designed to keep young learners academically engaged and confident during the break. As the CEO and founder of Kinder Ready Tutoring, Elizabeth Fraley brings her deep expertise in early childhood education to support students in retaining knowledge, building essential academic skills, and staying inspired to learn beyond the classroom. Under the direction of...

Read more

Kinder Ready's CEO Elizabeth Fraley, Announces an Expert Guide to Help Families Choose the Right Private School for Their Children

April 11, 2025 7:00 AM

Kinder Ready Elizabeth Fraley announces an expert guide designed to help families navigate the overwhelming task of choosing a private school that aligns with their child's academic, emotional, and social development needs. Leveraging her extensive experience in early childhood education, she has developed a comprehensive resource to simplify decision-making for parents. Through personalized consultations and educational resources, Kinder Ready...

Read more

VoluMetrix Wins People’s Choice Award at American College of Cardiology NIH-NHLBI Company Showcase

April 10, 2025 9:00 AM

VoluMetrix, an innovative leader in non-invasive cardiovascular monitoring solutions, is proud to announce that it has been awarded the People's Choice Award at the ACC25-NHLBI Company Showcase, held during the American College of Cardiology's Annual Scientific Session in Chicago. The prestigious event, hosted on March 29 in the exhibit hall's Future Hub, featured presentations from four cutting-edge companies selected from a competitive pool of...

Read more

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

April 9, 2025 9:15 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing difficult to treat cancers, today announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment. As part of the segment, Dr. Bissonnette discussed key highlights from...

Read more

BRK Technology Driving Sustainability With Algae Biofuels

April 9, 2025 9:00 AM

BRK Technology Co., Limited is excited to highlight how algae biofuels will play a critical role in helping companies meet their emission reduction targets in the years ahead. As businesses face increasing pressure to reduce their carbon footprints, algae biofuels offer a sustainable and scalable solution for achieving environmental goals while maintaining operational efficiency. Algae biofuels, derived from algae species cultivated in...

Read more

Bionoid Pharma Inc. Engages Aloba, Awomolo & Partners as External Auditor for 2024 Financial Statements

April 9, 2025 7:30 AM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) today announced it has engaged Aloba, Awomolo & Partners, a PCAOB-registered accounting firm, as its independent external auditor for the fiscal year ended December 31, 2024. This engagement underscores Bionoid's commitment to robust financial governance and transparency, aligning with its strategic initiatives to enhance market presence and shareholder value. "We are pleased to welcome Aloba,...

Read more

Ondine Biomedical Inc. - Economic Study Suggests c.£200 Million UK Savings

April 9, 2025 2:00 AM

Ondine Biomedical Inc. (LON:OBI) announces that a new health economic analysis by the York Health Economics Consortium (YHEC) has confirmed that using Steriwave® nasal decolonization prior to major surgery delivers substantial net cost savings. YHEC has demonstrated that for every £1 spent on Steriwave to prevent surgical site infections (SSI), the NHS can save an average of £1.49 to £2.38 across major surgical specialties. With £38 to £107 net...

Read more

Vibrant Wellness Advances Hormone Testing With Panel Linking Hormones, Toxins, and Longevity Markers

April 8, 2025 1:00 PM

Vibrant Wellness, a leading biotech and CAP-accredited lab company, has launched the Hormone Zoomer, an innovative wet urine test that gives integrative medicine professionals a comprehensive view of hormone health, endocrine disruption, and aging-related factors. By measuring 20+ adrenal hormones, 30+ sex hormones, 13 endocrine disruptors, and markers tied to oxidative stress and bone turnover, the test helps clinicians make more informed...

Read more

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

April 8, 2025 9:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial with the addition of Butler Hospital's Memory and Aging Program, a nationally recognized research center affiliated with the Warren Alpert Medical School of Brown University, in Providence, Rhode Island. The site will support enrollment for the CALMA study evaluating IGC-AD1, IGC Pharma's investigational...

Read more

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

April 8, 2025 7:15 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's (TSE:4502/NYSE:TAK) initiation of Phase 3 clinical trial of mezagitamab (TAK-079), identified from BioInvent's proprietary n-CoDeR® antibody library....

Read more

Aspira Appoints Three New Directors, Executes $2.0 Million Equity Purchase Agreement

April 8, 2025 7:00 AM

Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of three new Directors to its Board of Directors. These appointments were part of a planned Board change, aligned with the upcoming annual shareholders meeting. Each of the three new appointees brings extensive resumes, with the first...

Read more

Porter Logistics Partners with Invensify to Transform Cold Chain Management with Advanced Temperature Monitoring Solutions

April 7, 2025 12:00 PM

Porter Logistics, the innovative logistics provider specializing in warehousing, distribution, and transportation solutions announced a strategic partnership with Invensify, the inventors of the world's most power efficient quantum cold chain shippers. This collaboration comes as Porter Logistics announces the leasing of a 145,000 square-foot cold chain facility, creating a significant advancement in temperature-controlled logistics. The...

Read more